Andreas Oser has been working in the IP field since 1991, became German and European patent attorney in 1995 and is managing partner at Prüfer & Partner since 2002.
In addition he holds an LL.M. degree in International Intellectual Property Laws (University of Hagen). Prior to working in the IP field, he studied chemistry at the University of Freiburg i. Brsg., and then conducted his Ph.D. and postdoc studies at the Max Planck Institute for Biochemistry in Munich.
Mr Oser’s primary areas of expertise are chemistry, pharmaceuticals, life science and biotechnology, in particular: biological materials, DNA-related inventions and vaccines; therapeutic and diagnostic methods; medical products & devices and targeted drug delivery; polymers and fibre materials; semiconductors, LEDs, OLEDs and other optical materials and optoelectronic devices; and batteries and their components.
His activities include: patent prosecution (drafting, examination); a high number of opposition and appeal proceedings at the European Patent Office; patent litigation (patent infringement proceedings before German courts, nullity proceedings up to the highest instance, the Federal Supreme Court; also covering coordinated and complex EU-wide litigation activities); as well as infringement and validity opinions, freedom-to-operate (FTO) analyses, and due diligence.
Mr Oser was and is currently heavily involved in many litigation cases, among others related to medical devices and important drug products.
He is a member of: Chamber of Patent Attorneys; epi – European Patent Institute; Member of the Biotech Committee of the epi; AIPPI – International Association for the Protection of Intellectual Property; FICPI – International Federation of Intellectual Property Attorneys; LES – Licensing Executives Society; and GDCh – Gesellschaft Deutscher Chemiker.
Publications:
A. Oser in GRUR Int 1998, 648 (=IIC 30, 1-18 (1999)): “Patenting (Partial-)Gene Sequences
A. Oser, PATENTS & LICENSING 1998, 30: “EU Directive on Legal Protection of Biotech Inventions”
A. Oser & S. Bavec, AIPPI Japan 2004 (Vol. 49 No. 7), 503: “Biotech Inventions in Europe”
A. Oser in GRUR Int 2006, 539 (=IIC 37, 520-550 (2006)): “European Patent Litigation Agreement – Admissibility and Future of a Patent Dispute Regulation in Europe”
Author or co-author of 10 scientific publications
![LEGAL NEWS
In the recent case of Ketua Pengarah Hasil Dalam Negeri Malaysia v Ehsan Armada Sdn Bhd [2023] MLJU 2906, the Court of Appeal held that payment made by Ehsan Armada Sdn Bhd, a developer (“Taxpayer“) to the Lembaga Perumahan dan Hartanah Selangor (“LPHS”) to exempt itself from building low-cost housing, was not deductible under Section 33(1) of the Income Tax Act 1967 (“ITA”), as it is capital in nature.
Read more at https://globallawexperts.com/payment-for-exemption-from-building-low-cost-housing-is-not-tax-deductible/
.
.
.
.
#business #entrepreneur #motivation #success #marketing #money #love #mindset #entrepreneurship #inspiration #smallbusiness #instagood #businessowner #instagram #lifestyle #goals #life #startup #bhfyp #digitalmarketing #follow #motivationalquotes #branding #design #quotes #investment #fashion #finance #work](https://scontent-cdg4-1.cdninstagram.com/v/t51.2885-15/436764430_963066282188478_2199815877559299380_n.jpg?_nc_cat=110&ccb=1-7&_nc_sid=18de74&_nc_eui2=AeGxNhTuYQ4jc9w4r_e1nW1lpHdpjtV5ZF2kd2mO1XlkXV9IjQ4fXrloL5b_31QjEjCiSeEIx0Z-MqiAbW1LgYDt&_nc_ohc=kneHdMbrr9IAb7yBbGo&_nc_ht=scontent-cdg4-1.cdninstagram.com&edm=AM6HXa8EAAAA&oh=00_AfDMAt2SKTPocN4UPKV7L94s2Ttr_Sdo8LTdtQLINBr2MA&oe=6627F988)
